Resource data sheet
DNA Bank Top

pCSIIbsr-PKG-hNo.7 (#RDB19906)

Lentivirus vector of cGMP biosensor, protein kinase G (PKG) #7 with blasticidine resistance gene.


Drawn by SnapGene® software
Sequence information
(Assembled from experimentally sequenced data)
GenBank Flat File Format open
SnapGene file download
Publication Hirota, K., Endocrinology 163 (3): bqac005 (2022). PMID 35041746. [PubMed] [Article] [RRC of NBRP]
Test sheet Data Sheet open 
 
Clone info. Lentivirus vector of cGMP biosensor, protein kinase G (PKG) #7 with blasticidine resistance gene. PKG #7 is composed of cGMP-binding domain B from cGMP-dependent protein kinase IB, which binds specifically to intracellular cGMP, and of the ECFP and cp variant of Venus, cp173Venus, as the FRET donor and acceptor, respectively. See Fig.1 of Hirota, K. et al., Endocrinology, 163 (3): bqac005 (2022).
Vector backbone pCSIIbsr (plasmid)
Selectable markers Ampicillin (E. coli), BSD (mammalian cell). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Growth conditions LB+Ampicillin, 37℃
Gene/insert name human PRKG1 cDNA; Aequorea victoria GFP (ECFP, cp173Venus).
Depositor|Developer Matsuda, Michiyuki | Hirota, Keisho |

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested.((Hirota, K et al. Endocrinology. 163(3): bqac005, 2022) For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002).

Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.
Remarks Remember that you will be working with samples containing infectious virus.
Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Hirota, K et al. Endocrinology. 163(3): bqac005, 2022)。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。
付加的使用条件:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002).

InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。
備考 このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。
ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。

Catalog # Resource name Shipping form Fee
RDB19906 pCSIIbsr-PKG-hNo.7 DNA solution

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The pCSIIbsr-PKG-hNo.7 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB19906).

Reference section:

Hirota, K., Hirashima, T., Horikawa, K., Yasoda, A., Matsuda, M., C-type Natriuretic Peptide-induced PKA Activation Promotes Endochondral Bone Formation in Hypertrophic Chondrocytes. Endocrinology 163 (3): bqac005 (2022). PMID 35041746. [PubMed] [Article] [RRC of NBRP]

Further references such as user reports and related articles (go to bottom)


References

Original, user report and related articles

original Hirota, K., C-type Natriuretic Peptide-induced PKA Activation Promotes Endochondral Bone Formation in Hypertrophic Chondrocytes. Endocrinology 163 (3): bqac005 (2022). PMID 35041746. [PubMed] [Article] [RRC of NBRP]